IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

Core Insights - IMUNON, Inc. is advancing its pivotal Phase 3 trial, OVATION 3, for its investigational therapy IMNN-001, targeting newly diagnosed advanced ovarian cancer [1][4] - New translational data from the Phase 2 OVATION 2 Study will be presented at the AACR Special Conference, highlighting the potential of IMNN-001 [1][3] Company Overview - IMUNON is a clinical-stage biotechnology company focused on innovative treatments that utilize the body's natural mechanisms for effective responses against various diseases [5] - The company is developing its non-viral DNA technology, with its first modality, TheraPlas, aimed at gene-based delivery of cytokines for solid tumors [5] Product Details - IMNN-001 is based on IMUNON's proprietary TheraPlas technology, utilizing an IL-12 DNA plasmid vector in a nanoparticle delivery system to enhance anti-cancer immunity [2] - The therapy has shown clinically effective responses in advanced ovarian cancer, improving both progression-free survival (PFS) and overall survival (OS) when combined with standard chemotherapy [2][6] Clinical Trial Insights - The OVATION 3 study is currently enrolling patients at four sites, with plans for up to 46 additional sites [4] - Preliminary results from the OVATION 2 Study indicated a median 13-month increase in OS and a median 3-month increase in PFS for patients treated with IMNN-001 compared to standard care [6] - The use of PARP inhibitors in maintenance therapy further improved outcomes, with patients in the IMNN-001 treatment arm surpassing 5 years since randomization [6]